Most-Downgraded StocksMost-DowngradedNYSE:CTLT Catalent (CTLT) Stock Forecast, Price & News $37.34 +0.92 (+2.53%) (As of 02:10 PM ET) Add Compare Share Share Today's Range$36.11▼$37.3550-Day Range$31.86▼$67.5152-Week Range$31.45▼$115.33Volume856,367 shsAverage Volume3.63 million shsMarket Capitalization$6.72 billionP/E Ratio16.52Dividend YieldN/APrice Target$67.55 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalent MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside82.4% Upside$67.55 Price TargetShort InterestHealthy3.46% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.36Based on 13 Articles This WeekInsider TradingSelling Shares$105,903 Sold Last QuarterProj. Earnings Growth91.84%From $0.98 to $1.88 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.18 out of 5 starsMedical Sector14th out of 1,006 stocksPharmaceutical Preparations Industry5th out of 492 stocks 4.1 Analyst's Opinion Consensus RatingCatalent has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $67.55, Catalent has a forecasted upside of 82.4% from its current price of $37.04.Amount of Analyst CoverageCatalent has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.46% of the outstanding shares of Catalent have been sold short.Short Interest Ratio / Days to CoverCatalent has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalent has recently increased by 3.31%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalent does not currently pay a dividend.Dividend GrowthCatalent does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalent has received a 72.90% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services", "Clinical research services", and "Pharmacovigilance services" products. See details.Environmental SustainabilityThe Environmental Impact score for Catalent is -0.85. Previous Next 3.0 News and Social Media Coverage News SentimentCatalent has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Catalent this week, compared to 8 articles on an average week.Search Interest62 people have searched for CTLT on MarketBeat in the last 30 days. This is an increase of 182% compared to the previous 30 days.MarketBeat Follows10 people have added Catalent to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,903.00 in company stock.Percentage Held by InsidersOnly 0.58% of the stock of Catalent is held by insiders.Percentage Held by Institutions99.38% of the stock of Catalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalent are expected to grow by 91.84% in the coming year, from $0.98 to $1.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalent is 16.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalent is 16.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 93.97.Price to Earnings Growth RatioCatalent has a PEG Ratio of 4.91. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCatalent has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalent (NYSE:CTLT) StockCatalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory managRead More Receive CTLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter. Email Address CTLT Stock News HeadlinesMay 31, 2023 | morningstar.comCatalent Inc CTLT Stock QuoteMay 25, 2023 | americanbankingnews.comDeutsche Bank Aktiengesellschaft Boosts Catalent (NYSE:CTLT) Price Target to $37.00May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 25, 2023 | americanbankingnews.comMorgan Stanley Trims Catalent (NYSE:CTLT) Target Price to $50.00May 25, 2023 | americanbankingnews.comCatalent (NYSE:CTLT) Lowered to Neutral at JPMorgan Chase & Co.May 24, 2023 | finance.yahoo.comCatalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy DevelopmentMay 24, 2023 | americanbankingnews.comCatalent, Inc. to Post Q3 2023 Earnings of ($0.22) Per Share, William Blair Forecasts (NYSE:CTLT)May 24, 2023 | americanbankingnews.comBarclays Trims Catalent (NYSE:CTLT) Target Price to $35.00May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 24, 2023 | americanbankingnews.comCatalent (NYSE:CTLT) Shares Gap Down After Analyst DowngradeMay 23, 2023 | msn.comMorgan Stanley Maintains Catalent (CTLT) Overweight RecommendationMay 23, 2023 | msn.comRBC Capital Reiterates Catalent (CTLT) Outperform RecommendationMay 22, 2023 | seekingalpha.comCatalent cut to Neutral at JPMorgan on near-term outlookMay 22, 2023 | msn.comBaird Maintains Catalent (CTLT) Neutral RecommendationMay 22, 2023 | markets.businessinsider.comWhat To Know About JP Morgan's Downgrade of CatalentMay 22, 2023 | seekingalpha.comCatalent: Business Turnaround Is A Cost Reduction OdysseyMay 22, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Sell Rating on Catalent (CTLT)May 22, 2023 | americanbankingnews.comCatalent (NYSE:CTLT) PT Lowered to $35.00 at Robert W. BairdMay 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Catalent (CTLT) and Intercept Pharma (ICPT)May 21, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Catalent (NYSE:CTLT)May 21, 2023 | reuters.comCatalent cuts annual forecast hurt by operational challengesMay 21, 2023 | msn.comWhy Shares of Catalent Were Up FridayMay 20, 2023 | seekingalpha.comCatalent jumps 14% to reverse losses despite guidance cutMay 20, 2023 | americanbankingnews.comBrokers Offer Predictions for Catalent, Inc.'s Q3 2023 Earnings (NYSE:CTLT)May 19, 2023 | msn.comCatalent cuts forecast, delays results again as challenges mountMay 19, 2023 | msn.comCatalent Shares Climb After Positive Comments About the Firm's BusinessMay 19, 2023 | investorplace.comCatalent (CTLT) Stock Surges Despite Second Earnings DelaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CTLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter. Email Address CTLT Company Calendar Last Earnings11/01/2021Today5/31/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:CTLT CUSIPN/A CIK1596783 Webwww.catalent.com Phone(732) 537-6200Fax732-537-6480Employees19,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$67.55 High Stock Price Forecast$145.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+85.6%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.26 Trailing P/E Ratio16.11 Forward P/E Ratio37.14 P/E Growth4.91Net Income$503 million Net Margins8.62% Pretax Margin10.60% Return on Equity11.40% Return on Assets5.14% Debt Debt-to-Equity Ratio0.86 Current Ratio1.91 Quick Ratio1.38 Sales & Book Value Annual Sales$4.83 billion Price / Sales1.36 Cash Flow$5.71 per share Price / Cash Flow6.38 Book Value$26.76 per share Price / Book1.36Miscellaneous Outstanding Shares180,090,000Free Float179,045,000Market Cap$6.56 billion OptionableOptionable Beta1.17 Key ExecutivesAlessandro MaselliPresident, Chief Executive Officer & DirectorRicky HopsonChief Financial OfficerKay SchmidtSenior Vice President-Technical OperationsLim Chin WeiManager-Global Scientific AffairsJulien MeissonnierChief Scientific Officer & Vice PresidentKey CompetitorsRoivant SciencesNASDAQ:ROIVGrifolsNASDAQ:GRFSIonis PharmaceuticalsNASDAQ:IONSIntra-Cellular TherapiesNASDAQ:ITCIIVERIC bioNASDAQ:ISEEView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 4,013 shares on 5/26/2023Ownership: 0.016%Mountain Pacific Investment Advisers Inc. IDBought 342 shares on 5/23/2023Ownership: 0.110%Toroso Investments LLCBought 5,227 shares on 5/23/2023Ownership: 0.003%Old North State Trust LLCBought 3,349 shares on 5/23/2023Ownership: 0.002%Ameriprise Financial Inc.Bought 1,109,802 shares on 5/22/2023Ownership: 0.728%View All Insider TransactionsView All Institutional Transactions CTLT Stock - Frequently Asked Questions Should I buy or sell Catalent stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares. View CTLT analyst ratings or view top-rated stocks. What is Catalent's stock price forecast for 2023? 11 brokers have issued twelve-month price targets for Catalent's stock. Their CTLT share price forecasts range from $28.00 to $145.00. On average, they expect the company's share price to reach $67.55 in the next year. This suggests a possible upside of 85.6% from the stock's current price. View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts. How have CTLT shares performed in 2023? Catalent's stock was trading at $45.01 at the start of the year. Since then, CTLT stock has decreased by 19.1% and is now trading at $36.40. View the best growth stocks for 2023 here. Are investors shorting Catalent? Catalent saw a drop in short interest in April. As of April 15th, there was short interest totaling 5,850,000 shares, a drop of 8.6% from the March 31st total of 6,400,000 shares. Based on an average trading volume of 2,920,000 shares, the days-to-cover ratio is currently 2.0 days. View Catalent's Short Interest. How were Catalent's earnings last quarter? Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings data on Monday, November, 1st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.06. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a trailing twelve-month return on equity of 11.40% and a net margin of 8.62%. During the same period in the previous year, the business posted $0.33 earnings per share. Read the conference call transcript. What ETFs hold Catalent's stock? ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Alger 35 ETF (ATFV), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), VanEck Pharmaceutical ETF (PPH), Invesco Dynamic Biotechnology & Genome ETF (PBE), SPDR S&P Pharmaceuticals ETF (XPH), First Trust Health Care AlphaDEX Fund (FXH) and Harbor Health Care ETF (MEDI). What guidance has Catalent issued on next quarter's earnings? Catalent updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.25 billion-$4.35 billion, compared to the consensus revenue estimate of $4.44 billion. What is John R. Chiminski's approval rating as Catalent's CEO? 391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Catalent own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO). What is Catalent's stock symbol? Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT." Who are Catalent's major shareholders? Catalent's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.95%), Artisan Partners Limited Partnership (4.30%), State Street Corp (4.00%), Veritas Asset Management LLP (3.82%), American Century Companies Inc. (2.44%) and Geode Capital Management LLC (2.07%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph. View institutional ownership trends. How do I buy shares of Catalent? Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalent's stock price today? One share of CTLT stock can currently be purchased for approximately $36.40. How much money does Catalent make? Catalent (NYSE:CTLT) has a market capitalization of $6.56 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.26 on an earnings per share basis. How many employees does Catalent have? The company employs 19,000 workers across the globe. How can I contact Catalent? Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480. This page (NYSE:CTLT) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.